Tumor cell-secreted exosomal miR-22-3p inhibits transgelin and induces vascular abnormalization to promote tumor budding
Yaju Feng,Lumeng Wang,Ting Wang,Ying Li,Qingqing Xun,Renya Zhang,Lin Liu,Lei Li,Wei Wang,Yixuan Tian,Lili Yang,Xiao Zhi,Bijiao Zhou,Xin Chen,Tao Sun,Yanrong Liu
DOI: https://doi.org/10.1016/j.ymthe.2021.02.009
IF: 12.91
2021-06-01
Molecular Therapy
Abstract:<p>Tumor budding (TB) is considered a histomorphological marker of poor prognosis in patients with breast cancer (BC). Tumor vasculature is disordered and unstable in BC, which causes restricted drug delivery, hypoxia, and tumor metastasis. Traditional anti-angiogenic treatments cause extreme hypoxia, increased invasion, metastasis, and drug resistance due to blood vessel rarefaction or regression. Therefore, the application of anti-angiogenic strategies for vascular normalization in tumors is crucial to improve therapeutic efficacy in BC. In the present study, we found that transgelin (TAGLN) promoted the normalization of tumor vessels by regulating the structure and function of endothelial cells, and knockout of TAGLN in tumor-bearing mice resulted in tumor vessel abnormalization, increasing in epithelial-mesenchymal transition characteristics of tumor cells, and promotion of TB. Moreover, BC cells secrete exosomal miR-22-3p that mediates tumor vessel abnormalization by inhibiting transgelin. We demonstrated for the first time that transgelin plays an essential role in tumor vessel normalization, and thus, it impairs TB and metastasis. Additionally, the findings of this study indicate that exosomal miR-22-3p is a potential therapeutic target for BC.</p>
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology